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Introduction. Secondary hyperparathyroidism is common in chronic kidney disease. Parathyroidectomy is indicated in refractory
hyperparathyroidism when medical treatments and so the parathyroid hormone levels cannot be lowered to acceptable values
without causing significant hyperphosphatemia or hypercalcemia. The aim of this study is to compare the efficacy and safety of
total parathyroidectomy with subcutaneous forearm autotransplantation with total parathyroidectomy with intramuscular
forearm autotransplantation. Materials and Methods. A single-center retrospective cohort study of total parathyroidectomy with
forearm autotransplantation from January 2002 to February 2013 was performed. According to the surgical technique, patients
were divided into an intramuscular group (Group 1) and a subcutaneous group (Group 2). 38 patients with secondary
hyperparathyroidism were enrolled; 23 patients were subjected to total parathyroidectomy with parathyroid tissue replanting in
the subcutaneous forearm of the upper nondominant limb, while 15 patients were subjected to replanting in the intramuscular
seat. Results. A total of 38 patients (56± 13 years) were enrolled. In both groups, the preoperative iPTH value was markedly
high, 1750± 619 pg/ml in the intramuscular autotransplantation group and 1527± 451 pg/ml in the subcutaneous
autotransplantation group (p = 0 079). Transient hypoparathyroidism was shown in 7 patients, and 1 patient showed persistent
hypoparathyroidism (p = 0 387). 2 patients showed persistent hyperparathyroidism (p = 0 816), and in 2 others was found
recurrent hyperparathyroidism (p = 0 816); 3 of them underwent autograftectomy. The anterior compartment of the forearm
nondominant limb was sacrificed in 1 case of intramuscular autotransplantation with functional arm deficit. Conclusions. The
efficacy and safety of parathyroid tissue autotransplantation in the subcutaneous forearm of the upper nondominant limb is
confirmed with a good rate of tissue engraftment and with a comparable number of postsurgical transient and persistent
hypoparathyroidism and hyperparathyroidism incidence in both techniques. Furthermore, this technique preserves arm
functionality in the case of autograftectomy. Consequently, it is our opinion that total parathyroidectomy with subcutaneous
forearm autotransplantation is currently the best choice.
1. Introduction
Secondary hyperparathyroidism (SHPT) is common in
chronic kidney disease (CKD) particularly in dialysis patients,
and it is responsible for mineral bone disorders (MBD) and
cardiovascular diseases [1, 2]. SHPT is characterized by an
increase in the parathyroid hormone (PTH) synthesis and
secretion and progressive parathyroid gland hyperplasia.
There is an increase in the prevalence of SPTH (intact PTH
(iPTH)> 65 pg/ml) related to the decline of eGFR levels.
SHPT is present in approximately 12% of those with eGFR
values> 80ml/min/1.73m2, 17% of those with an eGFR of
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70–79ml/min/1.73m2, 21% of those with an eGFR between
60 and 69ml/min/1.73m2, and 56% of those with an
eGFR< 60ml/min/1.73m2 [2]. The improvement of medical
treatment and haemodialysis regimen in patients with CKD
resulted in the decrease of severe renal hyperparathyroidism
(rHPT) requiring parathyroid surgery [3, 4]. There is general
agreement in suggesting parathyroidectomy in patients with
CKD stages 3–5 D with severe SHPT who fail to respond to
pharmacological therapy or when the therapy results in unac-
ceptable rises in levels of serum calcium and/or phosphorus
(as occurs frequently using calcitriol or vitamin D analogues)
and also when medical management is not tolerated because
of adverse side effects. There are three surgical approaches
for parathyroidectomy: subtotal parathyroidectomy (sPTX),
total parathyroidectomy (tPTX), and total parathyroidec-
tomy with parathyroid tissue autotransplantation (AT) in
the sternocleidomastoid muscle or the intramuscular or sub-
cutaneous forearm of the nondominant limb. A consensus
on the best operative management is lacking, and currently,
there is no general agreement regarding the best therapeutic
approach. The efficacy and safety of different surgical tech-
niques are unclear, because the studies conducted to compare
the replanting methods were performed on limited patient
samples and reaching nonunivocal conclusions. Total para-
thyroidectomy (tPTX) with autotransplant performed by an
experienced surgeon effectively reduces the levels of PTH, cal-
cium, and phosphorus and also maintains a parathyroid tis-
sue necessary for the proper functioning of the mineral
metabolism [5–19]. The recurrence of hyperparathyroidism
at the site of implantation is a serious complication, which
occurs with a frequency between 7 and 9%. Autograftectomy,
often needed in the case of SHPT recurrence, when per-
formed in an intramuscular site of the forearm, often
imposes the sacrifice of muscle tissue resulting in functional
damage [3, 14, 15, 20, 21].
2. Aim of The Study
The aim of this study is to compare the efficacy and safety
of tPTX with subcutaneous forearm AT with tPTX with
intramuscular forearm AT and to evaluate the long-term
follow-up of patients in the two surgical techniques.
3. Materials and Methods
3.1. Study Design and Subjects.We performed a retrospective
cohort study on 38 patients, from January 2002 to February
2013, at the General Surgery of the Hospital of Brescia with
SHPT in haemodialysis regimen submitted to total parathy-
roidectomy (tPTX) with parathyroid tissue autotransplanta-
tion (AT) in the intramuscular (Group 1) or subcutaneous
(Group 2) site of the upper nondominant forearm.
3.2. Inclusion Criteria. Inclusion criteria include patients
aged >18 years and <75 years with SHPT with surgery
indication.
3.3. ExclusionCriteria.Exclusion criteria include patients over
75 years of age, patients with severe comorbidity with contra-
indicated surgery or ASA risk score over 3, primary or tertiary
hyperparathyroidism, parathyroid carcinoma, parathyroma-
tosis, and mediastinal parathyroid gland localization.
3.4. Surgery Indications. According to guidelines and experts’
opinions, our surgical indications were as follows: severe renal
HPT refractory to medical treatment (e.g., iPTH> 800 pg/ml,
hypercalcemia, and hyperphosphatemia), uncontrollable
renal secondary hyperparathyroidism on cinacalcet, intoler-
ance to medical therapy due to adverse effects, expected
long-term survival with severe symptomatic renal HPT
including pruritus, intractable bone pain, advanced osteopae-
nia/osteoporosis, calcinosis and calciphylaxis, severe osteitis
fibrosa or high bone turnover, erythropoietin-resistant ane-
mia, and dilated cardiomyopathy [3, 6–8, 10].
3.5. Preoperative and PostoperativeManagement and Surgical
Technique. All patients were investigated preoperatively by
neck ultrasound colour Doppler imaging (neck US/CD) and
99mTc-methoxyisobutylisonitrile (MIBI) scintigraphy [22]
of the neck and mediastinum. Total parathyroidectomy
(tPTX) includes careful identification and resection of all four
parathyroid glands with bilateral cervical thymectomy to
remove any supernumerary glands and parathyroid nests. A
70% intraoperative drop from the baseline levels after para-
thyroid gland tissue removal was considerate appropriate
during parathyroidectomy [23]. All parathyroids were mea-
sured and weighed before their reimplantation assessing
their viability and integrity. For autotransplantation (AT),
the most normal-appearing gland should be minced into
10–20 1mm3 pieces [5, 6, 10, 23]. Twenty-three patients
were submitted to tPTX with parathyroid tissue AT in the
subcutaneous forearm of the upper nondominant limb,
while 15 patients were submitted to parathyroid tissue AT
in the intramuscular forearm of the upper nondominant
limb. Cryopreservation of parathyroid tissue was routinely
performed in 21 patients until December 2013. Cryopreser-
vation was not performed in the remaining 17 patients
according to increasing evidence that the need for delayed
autotransplantation is low (1%) and that the success rate of
parathyroid autotransplantation is poor after cryopreserva-
tion [24–28]. Moreover, delayed autotransplantation was
never required in our experience. Monitoring of plasma cal-
cium levels was carried out by blood sampling every 8 hours
for the first 2 days during the postoperative course. Below
the threshold value of 7.8mg/dl, an infusion of calcium glu-
conate was performed until stabilization of the serum cal-
cium within normal values. Considering the criteria of
reference rate for the method during postoperative follow-
up, patients were classified as having hypoparathyroidism
(<6 months with iPTH< 10 pg/ml), persistent postopera-
tive hypoparathyroidism (>6 months with iPTH< 10pg/ml),
transient postsurgical hyperparathyroidism (iPTH>70pg/ml;
<6 months), persistent postsurgical hyperparathyroidism
(iPTH>70pg/ml; >6 months), and recurrence postsurgical
hyperparathyroidism (new onset of iPTH> 70 pg/ml during
follow-up). The indication for autograftectomy was based on
iPTH greater than 800 pg/ml not responding to medical
therapy and hypertrophy of the implanted tissue detected
by imaging methods [3, 6–8, 10, 11, 22, 23]. Patients with
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recurrent secondary hyperparathyroidism (rSHPT) follow-
ing total parathyroidectomy and autotransplantation were
assessed by locoregional US/CD and MIBI scintigraphy
of the neck and mediastinum and by a modified Casanova
test [29] to discriminate between the graft-bearing arm
and the neck as the site of the recurrence. Patients under-
went long-term follow-up and iPTH assay at 6, 12, 24, 36,
and 60 months.
3.6. Laboratory Measurements. Serum calcium (mg/dl) and
serum phosphorus (mg/dl) were measured using stan-
dard automated techniques. Parathyroid hormone (iPTH)
(pg/ml) was measured using a two-site assay that measures
“intact” hormones.
3.7. Statistical Analysis. Data management and analysis were
performed using IBM® SPSS® Statistics 20 for Windows®
software (IBM Corporation, New Orchard Road Armonk,
New York, USA). All continuous variables were expressed
as mean± standard deviation, and categorical variables were
expressed as numbers (percentage). Student’s t-tests or
Mann–Whitney U test was performed to determine differ-
ences between groups, as appropriate. Binomial test or chi-
square test was used for the comparison of categorical
data. A probability value of p < 0 05 was considered to be
statistically significant.
4. Results
A total of 38 patients (24 females and 12 males, mean age of
56± 13 years) were enrolled (Table 1). The two treatment
groups were homogeneous by sex, age, duration of haemo-
dialysis, and preoperative and postoperative iPTH values
(Table 2). In both groups, the preoperative iPTH value was
markedly high, 1750± 619 pg/ml in the intramuscular AT
group and 1527± 451 pg/ml in the subcutaneous AT group
(p = 0 079, Figure 1). MIBI scintigraphy of the neck and
mediastinum and neck US/CD was performed in the preop-
erative period to identify the site of parathyroid hyperplasia.
No intraoperative findings of thyroid concomitant pathology
were recorded. Nobody had postoperative major complica-
tions and postsurgical bleeding, and there was no postopera-
tive mortality. No temporary or persistent lesions of the
recurrent nerve were reported. The postoperative parathy-
roid hormone decreased with a statistically significant differ-
ence (Figure 1, p < 0 001) in both study groups. Transient
hypoparathyroidism was shown in 7 patients, and 1 patient
showed persistent hypoparathyroidism (p = 0 387), both
cases controlled then by medical therapy. Two patients
showed transient hyperparathyroidism (p = 0 816), and 2
showed persistent hyperparathyroidism (p = 0 816). Recur-
rent hyperparathyroidism was found in 2 cases with
nonsignificant statistic difference between the two groups
(p = 0 816) (Table 2). Three autograftectomies were per-
formed (p = 748). The anterior compartment of the forearm
of the nondominant limb was sacrificed in 1 case of intra-
muscular AT with a functional arm deficit. The mean
follow-up was 106± 24 months for patients undergoing
intramuscular reimplantation and 103± 18 months for
patients undergoing subcutaneous reimplantation, with no
statistically significant differences (p = 0 710, Table 2). More-
over, the two groups of patients were homogeneous as
regards the iPTH and calcium serum levels, showing a statis-
tical homogeneity also during the follow-up.
5. Discussion
The need for parathyroidectomy in patients with end-stage
renal disease (ESRD) is common and increases with the dura-
tion of dialysis therapy [2–5, 14]. Calciomimetic and other
therapeutic agents, such as chelating phosphorus and vita-
min D analogues, have been shown to be effective in second-
ary hyperparathyroidism, modifying the timing and necessity
of parathyroidectomy in secondary and tertiary hyperpara-
thyroidism, even if many of these drugs have a high cost to
public health [3, 4, 7, 30, 31]. The poor response or specific
contraindications to medical treatment direct the choice
towards parathyroidectomy. Refractory hyperparathyroidism
is severe, persistent, and progressive elevation of iPTH which
cannot be lowered to acceptable levels with medical therapy
(including vitamin D and cinacalcet analogues) without
causing significant hyperphosphatemia or hypercalcemia.
Table 1: Baseline characteristics of patients and biochemical
analyses before and after total PTX with forearm AT.
Total population
n = 38
Male n (%) 14 (36.8)
Age (year) 56± 13
Dialysis vintage (months) 80± 44
Pre-iPTH (pg/ml) 1621± 532








12 months iPTH (pg/ml) 55± 70
24 months iPTH (pg/ml) 57± 72
36 months iPTH (pg/ml) 58± 76
60 months iPTH (pg/ml) 61± 93
Follow-up time after PTX + AT (months) 109± 19
Long-term hypoparathyroidism 1 (2.6)
Persistent hyperparathyroidism 2 (5.3)
Recurrence hyperparathyroidism 2 (5.3)
Autograftectomy 3 (7.9)
Data are show as mean ± standard deviation or number (%). Abbreviations:
PTX: total parathyroidectomy; AT: autotransplantation; Pre-iPTH:
preoperative intact-parathyroid hormone; Post-iPTH: postoperative intact-
parathyroid hormone; 6, 12, 24, 36, and 60 months iPTH: intact-
parathyroid hormone measurement at 6, 12, 24, 36, and 60 months,
respectively, after PTX + AT.
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There is no consensus on the acceptable PTH target level
that defines refractory hyperparathyroidism. We have con-
sidered iPTH> 800 pg/ml in symptomatic patients, thus,
with bone degenerative involvement, hyperphosphoremia,
hypercalcemia, pruritus, and osteoarticular pain. Other
authors used the KDIGO guideline indicating the iPTH tar-
get threshold for treatment, a value which is nine times above
the upper limit of a normal PTH assay (i.e., 585 pg/ml if the
upper range of the normal assay is 65 pg/ml), even though a
parathyroidectomy is generally not performed at this value.
Severe hyperparathyroidism that is refractory to medical
therapy and associated with hypercalcemia (in the absence
of medications such as calcitriol, vitamin D, or calcium-
containing phosphate binders) suggests tertiary hyperpara-
thyroidism, in which there is autonomous secretion of PTH
that is not responsive to the plasma calcium concentration
[3, 5, 7, 8, 10, 11, 30–35].
The different sites for the reimplantation after parathy-
roidectomy both in the first intervention and in the relapses
with autograftectomy are currently debated. Some studies
have shown similar outcomes regarding intramuscular or
subcutaneous implantation [5, 10, 12–15, 28, 36–39]. The
November 2013 K/DOQI guideline confirmed that the
choice of procedure may be at the discretion of the surgeons
involved, and accordingly, in our center, parathyroidectomy
with autotransplantation in the subcutaneous site of the
upper nondominant forearm is the preferred procedure
[28]. MIBI scintigraphy is considered the best test for its high
sensitivity; however, its role in the localization of parathy-
roids before surgery is not shared and is of less impact com-
pared to operator surgery experience, while it seems more
useful in identifying the site of relapse of hyperparathyroid-
ism [22, 40, 41]. However, in this study to improve the
identification of the site of relapse and to evaluate a possible
infiltration of the surrounding tissue, this technique has
always been accompanied by the modified Casanova test
[29] and by an ultrasound of the parathyroid implant site.
As previously described in the literature, both surgical tech-
niques appear to be effective with regard to engraftment
and growth within the new anatomic site. In fact, the para-
thyroid tissue has high metabolic needs and also a high
capacity for implantation in highly vascularized sites, such
as muscle and subcutaneous tissue. The recurrence of sec-
ondary hyperparathyroidism with the need for autograf-
tectomy is an event that occurs in 5–7.5% of cases
according to the literature, but in recent studies, it was
also shown to be higher than 9% with an increased risk
for implantation of parathyroid tissue at the intramuscular
site. According to previous studies, in the intramuscular
AT, there is an increase in intraoperative time correlated
with the greater difficulty for the intervention, and in the
case of autograftectomy, it implies the sacrifice of an
Table 2: Comparison of group that underwent total PTX with subcutaneous forearm AT and group that underwent total PTX with
subcutaneous intramuscular forearm AT.
Intramuscular group Subcutaneous group p value
n = 16 n = 22
Male 6 (37.5) 8 (36.4) 0.105
Age (year) 51± 14 60± 12 0.275
Dialysis vintage (months) 89± 37 73± 47 0.386
Pre-iPTH (pg/ml) 1750± 619 1527± 451 0.079
Post-iPTH (pg/ml) 63± 78 53± 66 0.831
<10 3 (18.8) 5 (22.7) 0.767
10–70 11 (68.8) 15 (68.2) 0.970
>70 2 (12.2) 2 (9.1) 0.919
6 months iPTH (pg/ml) 58± 66 53± 68 0.879
<10 0 (0.0) 1 (4.5) 0.387
10–70 15 (93.8) 20 (90.9) 0.748
>70 1 (6.3) 1 (4.5) 0.816
12 months iPTH (pg/ml) 60± 71 52± 69 0.819
24 months iPTH (pg/ml) 63± 77 53± 69 0.746
36 months iPTH (pg/ml) 64± 81 54± 74 0.756
60 months iPTH (pg/ml) 66± 101 57± 89 0.708
Follow-up time after PTX + AT (months) 106± 24 103± 18 0.710
Long-term hypoparathyroidism 0 (0.0) 1 (4.5) 0.387
Persistent hyperparathyroidism 1 (6.3) 1 (4.5) 0.816
Recurrence hyperparathyroidism 1 (6.3) 1 (4.5) 0.816
Autograftectomy 1 (6.3) 2 (9.1) 0.748
Data are show as mean ± standard deviation or number (%). Abbreviations: PTX: total parathyroidectomy; AT: autotransplantation; Pre-iPTH: preoperative
intact-parathyroid hormone; Post-iPTH: postoperative intact-parathyroid hormone; 6, 12, 24, 36, and 60 months iPTH: intact-parathyroid hormone
measurement at 6, 12, 24, 36, and 60 months after PTX + AT.
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important motor component of the forearm, with consequent
functional impairment and worsening of quality of life
[10–15, 23, 29, 37, 40, 41]. We showed a nonsignificant
difference between the two groups in the recurrence of
secondary hyperparathyroidism after parathyroidectomy
(only in 3 patients), while Hsu and Hung [37] showed a
significant difference between the two groups; this differ-
ence could be due to the low size of the sample (7.8%).
5.1. Limitations. Our study presents a relatively small cohort
of patients; therefore, it needs to be confirmed by further
clinical studies with a larger population. It seems that future
large-scale studies are needed to clarify these differences, and
the prognostic relevance remains to be proven with a larger
number of patients.
6. Conclusion
Despite the limitations of this study, the efficacy and safety of
parathyroid tissue AT in the subcutaneous forearm of the
upper nondominant limb is confirmed with a good rate of
tissue engraftment and with a comparable number of post-
surgical transient and persistent hypoparathyroidism and
hyperparathyroidism incidence in both techniques. Further-
more, this technique preserves arm functionality in the case
of autograftectomy. Consequently, it is our opinion that
total PTX with subcutaneous forearm AT is currently the
best choice.
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Figure 1: Bar charts with error bars. There were no significant statistical differences in preoperative iPTH (pre-iPTH: 1750± 619 pg/ml
versus 1527± 451 pg/ml, p = 0 079), postoperative iPTH (post-iPTH: 63± 78 pg/ml versus 53± 66 pg/ml, p = 0 831), and 6 months iPTH
value (6 months iPTH: 58± 66 pg/ml versus 53± 68 pg/ml, p = 0 879) between groups. Boxes represent means; error bars indicate
standard errors.
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